Follow

Xintela AB

Nasdaq First North GM Stockholm (Sweden)

Xintela is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Rights issue
Price
0.25 SEK
Subscription period
27 Jun - 07 Jul 2022
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
XINT
SE0007756903
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Xintela AB with ticker XINT
Status
Active
Amount of instruments
87 851 970
Currency
SEK
First trading date
22 Mar 2016
Exercise
Sign in to buy
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Private placement
Sign in to buy
Set-off issue
Sign in to buy
Rights issue
Sign in to buy
Exercise
Sign in to buy
Set-off issue
Sign in to buy
Directed issue
Sign in to buy
Private placement
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
XINT
SE0007756903
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Xintela AB with ticker XINT
Status
Active
Amount of instruments
87 851 970
Currency
SEK
First trading date
22 Mar 2016
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Private placement
Sign in to buy
Set-off issue
Sign in to buy
Rights issue
Sign in to buy
Set-off issue
Sign in to buy
Directed issue
Sign in to buy
Private placement
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
XINT TO1
SE0007783543
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Xintela AB with ticker XINT TO1
Status
Archived
Amount of instruments
Currency
SEK
Trading period
22 Mar 2016 - 08 Feb 2017
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for SEK 5.0 during the subscription period January 30, 2017 - February 10, 2017.
Update (17.03.2016): New equity right for trading, Xintela TO1.
Update (30.01.2017): Today begins the subscription period for warrants of series TO1.
Update (06.02.2017): Last day of trading of warrants of series TO1.
Exercise
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
XINT TO2
SE0014555074
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Xintela AB with ticker XINT TO2
Status
Archived
Amount of instruments
16 754 112
Currency
SEK
Trading period
19 Aug 2020 - 11 Nov 2020
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for the price which corresponds to seventy (70) percent of the volume weighted average price of the Company's share on Nasdaq First North GM Sweden during a period of ten (10) trading days immediately preceding, and including, October 30, 2020 prior to the exercise period. However, the subscription price cannot be less than SEK 1.92 per share. The subscription period with the supprt of warrants will take place from November 4, 2020 - November 18, 2020.
Update (18.08.2020): New equity right for trading, Xintela AB TO2.
Update (02.11.2020): Redemption price determined for warrants of series TO2.
Exercise
Sign in to buy
People
Evy Lundgren-Åkerlund
CEO
Gregory Batcheller
Chairman of the board
Lars Hedbys
Board member
Maarten de Chateau
Board member
Hans-Joachim Simons
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Scheeletorget 1
Zip code
223 81
City/district
Lund
Country
Sweden (SE)
Registration number
556780-3480
LEI code
549300SMDH1EOLCBQU68
First trade date
22 Mar 2016
Registration date
02 Apr 2009
Short name
Xintela

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More